Drug intelligence / Profile preview

xw001

Development stage: Phase 2
Lead developer: Sciwind Biosciences
Modality: Peptides, Small Molecules
Administration: Oral, Inhalation

Overview

XW001 is an oral peptide therapeutic developed by Sciwind Biosciences for the treatment of respiratory syncytial virus (RSV) infections and pulmonary fibrosis. It is classified as both an antifibrotic and antiviral agent within the peptide drug class. The precise mechanism of action has not been defined publicly. As of March 2025, XW001 is in phase I/II clinical trials for RSV infection in children in China, administered via inhalation. There are no recent reports of development for pulmonary fibrosis or COVID-19[1][2][3][4].

Targets

IFNLR (Interferon Lambda Receptor)

Beyond the preview

Go deeper on xw001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xw001.

Explore the full profile